Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Q&A With US FDA Commissioner Scott Gottlieb

Executive Summary

US FDA Commissioner Scott Gottlieb sat down with the Pink Sheet and Medtech Insight reporters for an exclusive chat about his ongoing regulatory work and plans for the future.

Advertisement

Related Content

Are 180-Day Exclusivity Changes Moving Out Of Drug Pricing Plans?
Fast And Furious: How The First-To-Market Advantage Is Shrinking
Complete Response Letters: US FDA Trying To Identify Subsets For Public Release
2017 Complete Response Letters: Fewer Than 2016, Still More Than Years Past
J.P. Morgan Notebook Day 1: Tax Reform At Last, Allergan's Job Cuts, Teva Turnaround, Biogen's Cash, And Getting FDA-Friendly
J.P. Morgan Notebook Day 1: Tax Reform At Last, Allergan's Job Cuts, Teva Turnaround, Biogen's Cash, And Getting FDA-Friendly
Bumpy Ride Awaits Indian Firms In 2018 (And Then There’s Amazon)
Complete Response Letters: Firms See Value In Public Release, Don't Expect It Will Happen
Azar's HHS: Generic Certainty, REMS Fixes Can Lower Drug Prices
Gottlieb Promotes 'Team' Work For Product Reviews

Topics

Advertisement
UsernamePublicRestriction

Register

PS121928

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel